company background image
GBY logo

Sangamo Therapeutics DB:GBY Stock Report

Last Price

€0.56

Market Cap

€117.5m

7D

-32.9%

1Y

-62.9%

Updated

28 Mar, 2024

Data

Company Financials +

Sangamo Therapeutics, Inc.

DB:GBY Stock Report

Market Cap: €117.5m

GBY Stock Overview

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States.

GBY fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Sangamo Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sangamo Therapeutics
Historical stock prices
Current Share PriceUS$0.56
52 Week HighUS$1.62
52 Week LowUS$0.26
Beta1.44
1 Month Change-49.17%
3 Month Change11.33%
1 Year Change-62.86%
3 Year Change-94.79%
5 Year Change-94.71%
Change since IPO-94.91%

Recent News & Updates

Recent updates

Shareholder Returns

GBYDE BiotechsDE Market
7D-32.9%1.2%2.5%
1Y-62.9%34.7%7.0%

Return vs Industry: GBY underperformed the German Biotechs industry which returned 37% over the past year.

Return vs Market: GBY underperformed the German Market which returned 7.3% over the past year.

Price Volatility

Is GBY's price volatile compared to industry and market?
GBY volatility
GBY Average Weekly Movement40.5%
Biotechs Industry Average Movement5.7%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: GBY's share price has been volatile over the past 3 months.

Volatility Over Time: GBY's weekly volatility has increased from 26% to 40% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1995405Sandy Macraehttps://www.sangamo.com

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases.

Sangamo Therapeutics, Inc. Fundamentals Summary

How do Sangamo Therapeutics's earnings and revenue compare to its market cap?
GBY fundamental statistics
Market cap€117.52m
Earnings (TTM)-€238.16m
Revenue (TTM)€162.79m

0.7x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GBY income statement (TTM)
RevenueUS$176.23m
Cost of RevenueUS$221.56m
Gross Profit-US$45.32m
Other ExpensesUS$212.51m
Earnings-US$257.83m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.27
Gross Margin-25.72%
Net Profit Margin-146.30%
Debt/Equity Ratio0%

How did GBY perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.